Diagnostic Tests – Papanicolaou (Pap) Smear

1. What Is a Pap Smear?

The Papanicolaou (Pap) smear is a cytologic screening test used to evaluate cells taken from the cervix in order to identify early precancerous changes or established cervical cancer. By examining exfoliated cervical cells under a microscope, clinicians can detect abnormalities caused primarily by high-risk HPV infections long before they progress to invasive disease. The Pap smear is one of the most effective screening tools in medicine and has significantly reduced cervical cancer mortality in populations where it is routinely used.


2. When Is Pap Smear the Correct Answer?

A Pap smear is indicated as a routine screening test for cervical cancer. Screening begins at age 21, regardless of sexual history, or earlier if guidelines specify onset within three years of first sexual activity; however, age 21 is the standard U.S. board-style answer. The test should be repeated every 2–3 years, depending on the screening strategy and incorporation of HPV co-testing. Screening may be discontinued at age 65 if the patient has had a history of adequate, consistently negative prior screenings and no recent abnormalities. Pap testing is used specifically for asymptomatic women as part of preventive care.


3. What Is the Next Best Test If Results Are Positive?

When a Pap smear shows abnormal cytology—whether atypical cells, low-grade changes, or high-grade lesions—the next step is to perform a colposcopy, during which the cervix is carefully examined under magnification. Suspicious areas are then biopsied to obtain tissue for definitive diagnosis. Colposcopy provides direct visualization of the transformation zone, allowing clinicians to identify the exact location and severity of cervical lesions and to determine appropriate management based on biopsy results.

Diagnostic Tests – PET Scanning

1. What Is a PET Scan?

A PET scan, or positron emission tomography, is an imaging technique that evaluates the metabolic activity of tissues rather than just their anatomical structure. Unlike CT or MRI, which show size, shape, and location, a PET scan uses a radioactive glucose analog—most commonly 18-fluorodeoxyglucose (FDG)—to assess how active a lesion is metabolically. Cancer cells typically have high glucose consumption, so they absorb more FDG and appear as areas of increased signal. PET scanning is noninvasive and is frequently used to determine whether a mass seen on other imaging studies is biologically active or whether it represents benign or inactive tissue.


2. What Makes a PET Scan Abnormal?

A PET scan is considered abnormal when there is increased uptake of FDG, indicating heightened metabolic activity. Malignant cells consume glucose rapidly because of their elevated growth and division rates, so they typically “light up” on PET imaging. Some infections, granulomatous diseases (e.g., TB, sarcoidosis), and inflammatory processes can also show increased uptake, which is why PET is not 100% specific for cancer. However, a low or absent uptake suggests that a lesion is metabolically inactive or benign, even if it appears concerning on CT or MRI.


3. When Is PET Scan the Correct Answer?

PET scanning is particularly useful when evaluating whether a lesion—such as a lung mass—is truly malignant or whether areas seen on CT represent metastatic disease. In oncology cases, PET is the answer when determining the functional status of a suspicious mass or when assessing for occult metastasis before deciding on surgical management. For example, if a patient is diagnosed with a localized lung tumor, a PET scan helps determine if there are metabolically active lesions elsewhere in the chest or body. If a contralateral mass or mediastinal lymph node lights up on PET, the disease is considered metastatic and surgery is no longer curative. Conversely, if additional lesions show low uptake, they are likely benign, and the patient may proceed safely to surgery to remove the primary tumor.

Diagnostic Tests – Methylmalonic Acid (MMA) Level

Methylmalonic acid (MMA) is a metabolic compound that accumulates in the body when vitamin B12 is deficient. Because MMA rises early in B12 deficiency, it is more sensitive than simply measuring serum vitamin B12 levels. In contrast, homocysteine levels increase in both vitamin B12 deficiency and folic acid deficiency, making homocysteine less specific. Therefore, MMA is a key diagnostic marker when evaluating macrocytic anemia and suspected B12 deficiency, especially when initial tests are inconclusive.


MMA testing becomes particularly important when a patient presents with macrocytic anemia, hypersegmented neutrophils, or clinical features suggestive of vitamin B12 deficiency—such as peripheral neuropathy, glossitis, or a history of malabsorption—but has a normal or borderline serum B12 level. In these situations, B12 levels may not accurately reflect tissue-level deficiency. Thus, when the clinical scenario strongly points toward B12 deficiency but the measured B12 level appears normal, the correct next diagnostic step is to order an MMA level to confirm or rule out early or functional B12 deficiency.

Diagnostic Tests – PSA (Prostate-Specific Antigen)

1. What Is PSA?

Prostate-specific antigen (PSA) is a protein produced almost exclusively by prostatic epithelial cells. It circulates in the bloodstream at low levels in healthy men but can rise in a variety of prostate-related conditions. PSA is not specific for prostate cancer—it increases in benign prostatic hyperplasia (BPH), prostatitis, urinary retention, recent ejaculation, and even after prostate manipulation such as digital rectal exam or biopsy. After a total prostatectomy, PSA should fall to undetectable levels; therefore, any measurable PSA in this setting suggests persistent or recurrent disease. Because PSA reflects prostate activity, but not necessarily malignancy, it requires careful interpretation.

2. When Should PSA Testing Be Done?

Routine PSA screening is controversial because large population studies have not clearly demonstrated a reduction in prostate cancer–related mortality. As a result, board-style questions emphasize that PSA screening is not routinely recommended for asymptomatic men. However, if a patient specifically requests the test for reassurance or personal preference, it is appropriate to perform it after discussing risks and limitations. Thus, in test scenarios, PSA should be ordered when the patient actively asks for screening, or when it is part of the evaluation of known or suspected prostate pathology.


3. What Is the Most Accurate Test?

The most accurate diagnostic test for confirming prostate cancer is a prostate biopsy. Neither PSA nor imaging can definitively diagnose malignancy—only histologic examination can determine the presence and grade of cancer. Biopsy results not only establish the diagnosis but also provide Gleason scoring, which guides prognosis and management decisions.

4. What Test Is Done Next If PSA Is Elevated?

When a PSA level is elevated, the next step is to perform a digital rectal exam (DRE) to assess the prostate directly. If the DRE reveals a palpable nodule, area of induration, or asymmetry, the abnormal region should be biopsied. If the DRE is normal but PSA is persistently elevated or concerning, the next step is a transrectal ultrasound (TRUS) to visualize the prostate and identify areas to target for biopsy. If no clear lesion is detected despite high PSA levels, clinicians may proceed with systematic (“blind”) biopsies, sampling multiple regions of the prostate because cancer can be present even without a detectable mass.

Diagnostic Tests – Sentinel Node Evaluation

1. What Is Sentinel Node Evaluation?

Sentinel node evaluation, or sentinel lymph node biopsy (SLNB), is a diagnostic procedure used primarily in the management of breast cancer (and also melanoma). Its purpose is to determine whether cancer has begun to spread beyond the primary tumor into the regional lymph nodes. Because cancer metastasizes in an orderly fashion through lymphatic drainage, the sentinel node—the first lymph node that receives lymph flow from the tumor site—acts as an early indicator of metastatic spread. Examining this node helps determine staging, prognosis, and the need for further lymph node removal.

2. How Is Sentinel Node Evaluation Done?

The procedure involves injecting a tracer dye, radioactive substance, or both into the breast at or near the tumor or biopsy cavity during surgery. This material travels through the lymphatic system, and the first lymph node it reaches is identified as the sentinel node. The surgeon then removes this node and sends it for pathological analysis.

• If the sentinel node contains cancer cells, this indicates lymphatic spread, and a full axillary lymph node dissection may be performed to remove additional nodes.
• If the sentinel node is negative, it suggests that cancer has not yet metastasized regionally, and axillary dissection can be safely avoided, sparing the patient significant morbidity such as lymphedema.

3. When Is Sentinel Node Evaluation the Correct Answer?

A sentinel node biopsy is indicated after a diagnosis of breast cancer has already been established through either needle biopsy or excisional biopsy. You should choose sentinel node evaluation in cases where the patient has:

• An abnormal mammogram
• A breast mass that has been biopsied
• Confirmed invasive breast cancer

At this point, SLNB becomes the next best step because it provides essential staging information and helps determine whether cancer has begun to spread to the lymph nodes. It is particularly valuable because it can replace the need for full axillary lymph node dissection in patients whose sentinel node is free of cancer, thereby reducing surgical complications while still providing accurate staging.

Diagnostic Tests – Factor V Leiden Mutation

1. What Is Factor V Leiden?


Factor V Leiden is a genetic mutation that makes Factor V resistant to the inhibitory action of activated protein C (APC), one of the body’s natural anticoagulants. Normally, protein C slows the clotting cascade by inactivating Factor V; however, the Factor V Leiden mutation alters the structure of Factor V so that it no longer responds effectively to protein C. As a result, clotting continues unchecked, creating a hypercoagulable state. This condition is the most common inherited thrombophilia, significantly increasing a person’s risk of developing venous thromboembolism (VTE) such as deep vein thrombosis (DVT) or pulmonary embolism (PE).


2. When Do You Answer Factor V Leiden Mutation Testing?

Testing for the Factor V Leiden mutation is indicated in young patients who present with an unprovoked DVT or PE, especially when the event occurs without clear provoking factors such as recent surgery, trauma, or immobilization. Board-style scenarios often feature:

• A first-time clot in a young adult
• A thrombotic event after a long airplane flight or prolonged immobility
• A family history of recurrent clots

In these cases, Factor V Leiden testing is the most accurate test for identifying a hereditary cause of hypercoagulability. It is part of the evaluation when considering inherited thrombophilias.


3. What Other Tests Should Be Sent With It?

When evaluating a patient for possible inherited or acquired hypercoagulable states, several additional tests are typically ordered alongside Factor V Leiden. These include:

• Protein S levels – Low levels increase clotting risk.
• Protein C levels – Especially important when the case mentions skin necrosis, which may occur when patients with undiagnosed protein C deficiency receive warfarin.
• Lupus anticoagulant testing – Consider this when the patient has an unexplained prolonged PTT, recurrent spontaneous abortions, or autoimmune features; this suggests antiphospholipid syndrome.
• Antithrombin III deficiency testing – Suspect this when a patient shows resistance to heparin, as AT III is required for heparin’s anticoagulant effect.

Together, these tests help create a comprehensive picture of a patient’s thrombotic risk and identify whether the cause is inherited, acquired, or multifactorial.






​

Diagnostic Tests – Haptoglobin Levels


1. What Is Haptoglobin?

Haptoglobin is a plasma protein that binds freely circulating hemoglobin released from red blood cells during hemolysis. Under normal conditions, haptoglobin levels remain stable because little free hemoglobin circulates in the bloodstream. However, when red blood cells rupture—whether due to immune destruction, mechanical trauma, or inherited hemolytic disorders—large amounts of hemoglobin spill into the plasma. Haptoglobin binds this hemoglobin, forming complexes that are removed from circulation by the reticuloendothelial system. As a result, serum haptoglobin levels fall, making low haptoglobin a key indicator of intravascular hemolysis. Hemolysis is also typically accompanied by elevated LDH, increased reticulocyte count, and elevated indirect bilirubin due to increased RBC breakdown and compensatory marrow response.


2. When Do You Answer a Haptoglobin Level?

Haptoglobin should be ordered when a clinical scenario suggests acute hemolysis, particularly when a patient develops sudden-onset anemia that cannot be explained by gastrointestinal bleeding or other obvious sources of blood loss. Features that point toward hemolysis include jaundice, dark urine, elevated LDH, or a rapid drop in hemoglobin without external bleeding. In board-style questions, a combination such as acute anemia + no GI bleeding = hemolysis, making haptoglobin part of the appropriate workup. The test helps confirm hemolysis and distinguish it from other causes of anemia.

Diagnostic Tests: Osmotic Fragility Test​

Overview

The osmotic fragility test is a diagnostic laboratory test used primarily in hematology to identify red blood cell (RBC) membrane defects. It is most famously associated with hereditary spherocytosis, a condition in which RBCs lose membrane surface area and become spherical in shape. Because of their altered structure, these cells are more susceptible to destruction when exposed to certain osmotic conditions. The test helps clinicians confirm the diagnosis in patients presenting with hemolytic anemia and characteristic findings on peripheral smear.


How the Test Works

The osmotic fragility test evaluates how easily RBCs lyse when placed in hypotonic (dilute) saline solutions. Normal red cells have a biconcave shape, giving them a high surface area-to-volume ratio and allowing them to tolerate changes in osmotic pressure. In contrast, spherocytes—such as those seen in hereditary spherocytosis—have reduced membrane surface area, making them less flexible and less able to expand when water enters the cell.


When placed in increasingly hypotonic solutions, spherocytes absorb water more rapidly and lyse at higher saline concentrations than normal cells. The degree of hemolysis is measured by the amount of hemoglobin released into the solution. A higher-than-normal level of hemolysis at moderate hypotonicity indicates increased osmotic fragility.


When Osmotic Fragility Is the Best Answer

You should choose osmotic fragility testing when evaluating a patient with features suggestive of hereditary spherocytosis, particularly when the case includes:

• Hemolytic anemia, often chronic or recurrent
• Splenomegaly
• Spherocytes on peripheral blood smear
• Family history of similar episodes
• Pigmented (bilirubin) gallstones, which develop from chronic hemolysis

These key clinical clues, combined with laboratory findings, strongly support the use of osmotic fragility testing as part of the diagnostic work-up.

Diagnostic Tests – Leukocyte Alkaline Phosphatase (LAP) Score

Leukocyte alkaline phosphatase (LAP) is an enzyme found inside mature white blood cells, particularly neutrophils. The LAP score reflects the activity level of this enzyme within these cells. When neutrophils are increased in number and functioning normally, the LAP score rises proportionately. This means that a high LAP score suggests that the elevated white blood cell count is due to a reactive, healthy response—such as an infection or inflammation—rather than a malignant or dysfunctional process. Conversely, when neutrophils are increased in number but function abnormally, the LAP score remains low.


LAP becomes an important diagnostic tool when there is concern about chronic myelogenous leukemia (CML) versus a leukemoid reaction. Both conditions can present with extremely high white blood cell counts dominated by neutrophils. However, in CML, the neutrophils are part of a malignant proliferation and do not function normally, leading to a low LAP score. A patient with CML often has additional findings such as a markedly enlarged spleen, causing left upper quadrant abdominal discomfort or early satiety. In contrast, a leukemoid reaction—typically triggered by infection or severe stress—produces very high white counts as part of a normal physiological response, resulting in a high LAP score. Therefore, LAP is the answer when distinguishing between these two conditions in the setting of significant neutrophilia.